Regulation of inflammatory responses by neuregulin-1 in brain ischemia and microglial cells in vitro involves the NF-kappa B pathway
- 1.5k Downloads
We previously demonstrated that neuregulin-1 (NRG-1) was neuroprotective in rats following ischemic stroke. Neuroprotection by NRG-1 was associated with the suppression of pro-inflammatory gene expression in brain tissues. Over-activation of brain microglia can induce pro-inflammatory gene expression by activation of transcriptional regulators following stroke. Here, we examined how NRG-1 transcriptionally regulates inflammatory gene expression by computational bioinformatics and in vitro using microglial cells.
To identify transcriptional regulators involved in ischemia-induced inflammatory gene expression, rats were sacrificed 24 h after middle cerebral artery occlusion (MCAO) and NRG-1 treatment. Gene expression profiles of brain tissues following ischemia and NRG-1 treatment were examined by microarray technology. The Conserved Transcription Factor-Binding Site Finder (CONFAC) bioinformatics software package was used to predict transcription factors associated with inflammatory genes induced following stroke and suppressed by NRG-1 treatment. NF-kappa B (NF-kB) was identified as a potential transcriptional regulator of NRG-1-suppressed genes following ischemia. The involvement of specific NF-kB subunits in NRG-1-mediated inflammatory responses was examined using N9 microglial cells pre-treated with NRG-1 (100 ng/ml) followed by lipopolysaccharide (LPS; 10 μg/ml) stimulation. The effects of NRG-1 on cytokine production were investigated using Luminex technology. The levels of the p65, p52, and RelB subunits of NF-kB and IkB-α were determined by western blot analysis and ELISA. Phosphorylation of IkB-α was investigated by ELISA.
CONFAC identified 12 statistically over-represented transcription factor-binding sites (TFBS) in our dataset, including NF-kBP65. Using N9 microglial cells, we observed that NRG-1 significantly inhibited LPS-induced TNFα and IL-6 release. LPS increased the phosphorylation and degradation of IkB-α which was blocked by NRG-1. NRG-1 also prevented the nuclear translocation of the NF-kB p65 subunit following LPS administration. However, NRG-1 increased production of the neuroprotective cytokine granulocyte colony-stimulating factor (G-CSF) and the nuclear translocation of the NF-kB p52 subunit, which is associated with the induction of anti-apoptotic and suppression of pro-inflammatory gene expression.
Neuroprotective and anti-inflammatory effects of NRG-1 are associated with the differential regulation of NF-kB signaling pathways in microglia. Taken together, these findings suggest that NRG-1 may be a potential therapeutic treatment for treating stroke and other neuroinflammatory disorders.
KeywordsBioinformatics Gene expression Inflammation Ischemia Microarray Neuregulin Stroke Transcription factor-binding site (TFBS)
Bovine serum albumin
Conserved Transcription Factor-Binding Site Finder
Dulbecco’s modified Eagle’s media
External carotid artery
Enzyme-linked immunosorbent assay
Fetal bovine serum
Internal carotid artery
Inhibitory kappa B
Ingenuity Pathway Analysis
Middle cerebral artery
Middle cerebral artery occlusion
Nuclear factor kappa B
Polyvinylidene difluoride membranes
Reactive oxygen species
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
Transcription factor-binding sites
Tumor necrosis factor α
The actions of neuregulins have been demonstrated in normal brain function and in neuroprotection following cerebral ischemia. Studies from our laboratory and others demonstrated that neuregulin-1 (NRG-1) reduced ischemia-induced neuronal death in rodent models of focal stroke [1, 2, 3]. NRG-1 was neuroprotective with a therapeutic window of >13 h and significantly improved neurological function [2, 4]. Neuroprotection by NRG-1 was also associated with the inhibition of pro-inflammatory gene expression following ischemia [2, 3, 5, 6, 7, 8]. The anti-inflammatory effects of NRG-1 have also been shown in other animal models of neuroinflammation including cerebral malaria and nerve agent intoxication [9, 10] and in vivo using cultured macrophages and microglia [3, 11]. However, the cellular and molecular mechanisms involved in the immunomodulatory effects of NRG-1 remain unclear.
Neuronal death following ischemic stroke involves the induction of genes associated with a number of cellular functions, including apoptosis, inflammation, and oxidative stress [12, 13]. The initial inflammatory response following brain injury is mediated by the activation of its resident inflammatory cells, the microglia [14, 15, 16]. Activated microglia release inflammatory mediators such as reactive oxygen species (ROS), nitric oxide (NO), tumor necrosis factor α (TNF-α), and interleukin-1β (IL-1β) [17, 18, 19]. While the initial activation of microglia is the brain’s attempt to protect neurons, the over-activation of microglia leads to uncontrolled inflammation which exacerbates neuronal death [18, 20, 21]. Nuclear factor kappa B (NF-kB) is a transcription factor widely known to be associated with inflammatory responses following ischemia and other neuroinflammatory disorders [22, 23, 24]. There are five members of the NF-kB family which include p65 (RelA), RelB, c-Rel, p50/105 (NF-kB1), and p52/p100 (NF-kB2), which exist in unstimulated cells as homo or heterodimers bound to inhibitory kB (IkB) family proteins. Activation of the canonical NF-kB pathway triggers IkB kinase (IKK) activity, leading to phosphorylation and degradation of IkB proteins and the release of NF-kB p65/p50 heterodimers. The released p65/p50 NF-kB dimers translocate from the cytoplasm to the nucleus where they bind to specific DNA sequences and promote transcription of target genes [23, 24]. In the canonical pathway, NF-kB activation triggers the production of pro-inflammatory cytokines and NO [18, 25, 26]. Studies have shown that inhibition of the canonical NF-kB pathway prevents the production of pro-inflammatory cytokines [27, 28, 29]. The activation of the NF-kB alternative/non-canonical pathway involves NF-kB-inducing kinase (NIK), a member of the MAP kinase family, which activates IKKα, resulting in the translocation of RelB/p52 NF-kB heterodimers to the nucleus [30, 31, 32, 33, 34]. The alternative NF-kB pathway has been shown to stimulate the production of anti-apoptotic and anti-inflammatory molecules [31, 35, 36, 37, 38, 39]. The effects of NRG-1 have been shown to be mediated by NF-kB signaling during tumorigenesis in cancers and axonal myelination [40, 41, 42, 43, 44, 45]. Specifically, NRG-1 has been shown to activate NIK through its association with the NRG-1’s erbB receptors .
To identify transcriptional regulators involved in ischemia-induced inflammatory gene expression, we examined gene expression profiles of brain tissues following ischemia and NRG-1 treatment. Using Conserved Transcription Factor-Binding Site Finder (CONFAC) software, we performed computational analysis to predict transcriptional regulators of genes that were induced following ischemic stroke but were downregulated by NRG-1. CONFAC identifies conserved transcription factor-binding sites significantly over-represented in promoter regions of a set of genes of interest compared to random control set of genes . NF-kB was identified as one of the top potential regulators of NRG-1-suppressed genes following ischemia. Using N9 microglial cells, we observed that NRG-1 blocked the phosphorylation and degradation of IkB-α, leading to the attenuation of classical NF-kB activation. NRG-1 increased the nuclear translocation of the p52 subunit of NF-kB and the levels of anti-apoptotic cytokines G-CSF and IL-9, suggesting a role for the alternative NF-kB pathway. Understanding these mechanisms will provide insight into the molecular processes behind the neuroprotective and anti-inflammatory abilities of NRG-1.
Transient middle cerebral artery occlusion (MCAO)
All animals were treated humanely and with regard for alleviation of suffering and pain. All surgical protocols involving animals were performed by sterile/aseptic techniques and were approved by the Institutional Animal Care and Use Committee at Morehouse School of Medicine prior to the initiation of experimentation. Adult male Sprague-Dawley rats (250–300 g; Charles River Laboratory International, Inc., USA) were housed in standard cages in a temperature-controlled room (22 ± 2 °C) on a 12-h reverse light-dark cycle. Food and water were provided ad libitum.
Animals were randomly allocated into three groups: sham (control), middle cerebral artery occlusion (MCAO) + vehicle treatment (MCAO) and MCAO + NRG-1 (MCAO + NRG1). Rats were anesthetized with a ketamine/xylazine solution (100/10 mg/kg, i.p.) prior to surgery. After anesthesia administration, a rectal probe monitored the core body temperature and a Homoeothermic Blanket Control Unit (Harvard Apparatus, Hollister, MA) was used to ensure the body temperature maintained at 37 °C. Cerebral blood flow was monitored throughout the length of the surgery by a continuous laser Doppler flowmeter (Perimed, Ardmore, PA), with a laser Doppler probe placed 7 mm lateral and 2 mm posterior to bregma in a thinned cranial skull window.
Rats in the treatment groups (MCAO and MCAO + NRG1) were subjected to a left transient MCAO. MCAO was induced by the intraluminal suture method as previously described . Briefly, a 4-cm length 4-0 surgical monofilament nylon suture coated with silicon (Doccol Corp., Sharon, MA) was inserted from the external carotid artery (ECA) into the internal carotid artery (ICA) and then into the Circle of Willis, to occlude the origin of the left middle cerebral artery (MCA). After 1.5 h of ischemia, the nylon suture was removed and the ischemic brain was reperfused for 22.5 h before sacrifice. Rats in the sham control group underwent the same procedure as those in the treatment groups, but a filament was not inserted into the ICA. Animals were randomly assigned into treatment groups and either administered 50 μl of NRG-1β reconstituted with 1 % bovine serum albumin (BSA) in phosphate-buffered saline (PBS) (MCAO + NRG1; 20 μg/kg; EGF-like domain, R&D Systems, Minneapolis, MN) or vehicle (MCAO; 1 % BSA in PBS) All treatments were administered by bolus injection into the ICA through ECA immediately before MCAO. Animals were sacrificed 24 h after MCAO. All NRG-1 and vehicle treatment studies were performed in a blinded manner.
RNA preparation and microarray analysis
Microarray analysis was performed as we previously described [3, 48, 49]. Animals were sacrificed, and their brains removed 24 h following MCAO. Removed brains were sliced into 2-mm coronal sections (approximately +3.0 to −5.0 from bregma) using a brain matrix. Tissue from the ipsilateral tissue from the two middle slices (+1 to −3 from bregma) of MCAO treated (n = 3) and MCAO + NRG1 treated (n = 3) and sham animals (n = 3) were used for RNA isolation, while the two outer slices of tissue were used for staining with 2,3,5-triphenyltetrazolium chloride (TTC), in order to confirm infarct formation. Total RNA extraction was performed using TRIzol Reagent (Life Technologies, Rockville, MD, USA), cleaned (RNAqueous Kit Ambion, Austin, TX, USA), and converted to double-stranded complementary DNA (cDNA) (Invitrogen, Superscript Choice System, Carlsbad, CA, USA) using T7-(dT)24 primer. Cleanup of double-stranded cDNA used Phase Lock Gels (Eppendorf, Westbury, NY, USA)-Phenol/Chloroform/Isoamyl Alcohol (Sigma, St. Louis, MO, USA). cRNA was synthesized using a RNA transcript labeling kit (Enzo Diagnostics, Farmingdale, NY, USA). Biotin-labeled cRNA was cleaned up using a GeneChip Sample Cleanup Module (Affymetrix Inc., Santa Clara, CA, USA) and quantified using a spectrophotometer. Twenty micrograms of the in vitro transcription product was fragmented by placing at 94 °C for 35 min in fragmentation buffer. Following fragmentation, 15 μg of the biotinylated cRNA was hybridized to an Affymetrix Rat Genome U34A GeneChip. The chips were hybridized at 45 °C for 16 h, and then washed, stained with streptavidin-phycoerythrin, and scanned according to the manufacturing guidelines.
Microarray data analysis
Affymetrix Expression Console software (Affymetrix, Santa Clara, CA) was used for initial data processing. Affymetrix microarrays contain the hybridization, labeling, and housekeeping controls that help determine the success of the hybridizations. The Affymetrix Expression Analysis algorithm uses the Tukey’s biweight estimator to provide a robust mean signal value and the Wilcoxon’s rank test to calculate a significance or p value and detection call for each probe set. The detection p value is calculated using a discrimination score (R) for all probes. The discrimination score is a basic property of a probe pair that describes its ability to detect its intended target. It measures the target-specific intensity differences of the probe pair (perfect match (PM)–mismatch (MM)) relative to its overall hybridization intensity (PM + MM). Background estimation is provided by a weighted average of the lowest 2 % of the feature intensities. Mismatch probes are utilized to adjust the PM intensity. Linear scaling of the feature level intensity values, using the trimmed mean, is the default to make the means equal for all arrays being analyzed. False-negative and false-positive rates are minimized by subtracting nonspecific signal from the PM probe intensities and performing an intensity-dependent normalization at the probe set level. Calculation of fold change and the presence of genes in the tissue were analyzed in Microsoft Excel. Changes in gene expression were compared between the control (sham) and following MCAO and MCAO + NRG-1 treatment. Gene expression values that increased or decreased by twofold or more were statistically significant (p < 0.05) using two-way ANOVA. The list of genes upregulated twofold or more by ischemia and decreased 50 % or more by NRG-1 was analyzed using Ingenuity Pathway Analysis (IPA) software (Qiagen, Redwood City, CA; www.ingenuity.com) overlaid onto a global molecular network developed from information contained in the Ingenuity Knowledge Base. Fischer’ s exact test was used to calculate a p value determining the probability that each biological function and/or disease assigned to that network is due to chance alone. The functions, canonical pathways, and gene networks that were most significant to the dataset were identified. IPA identified 64 inflammatory genes that were upregulated twofold or more by MCAO and reduced 50 % or more by NRG-1.
Using CONFAC software, we further examined the IPA-identified inflammatory genes [47, 48]. A tab-delimited text file containing the gene name and RefSEQ ID of the clusters of interest (genes) was uploaded to the CONFAC web browser interface (http://confac.emory.edu/). CONFAC software identified mouse orthologs from the uploaded gene list (from UCSC and ENSEMBL genomes). CONFAC software next identified significantly conserved sequences (e value <0.001), which were analyzed for transcription factor-binding sites (TFBS) using MATCH™ software. The final output table consisted of the cohort list of genes (column) and the position weight matrix (collected in TRANSFAC® database) identified potential TFBS and the number of TFBS determined for each gene of interest. The CONFAC program then allowed for additional analysis using the Mann-Whitney U test, which facilitated the statistical analysis of TFBS over-represented in the sample dataset compared to the seven control random control datasets provided by CONFAC.
N9 microglial cell culture
The murine N9 microglial cell line was kindly provided by Dr. Celine Beamer (Department of Biomedical and Pharmaceutical Sciences, University Montana). N9 cells were cultured in Dulbecco’s modified Eagle’s media (DMEM) with 4 mM l-glutamine, supplemented with 10 % fetal bovine serum (FBS), streptomycin (100 U/ml), and penicillin (100 U/ml). The cells were maintained in 95 % air and 5 % CO2-humified atmosphere at 37 °C and were passaged every 3 days. For culturing with various stimulants, N9 cells were plated into 12-well plates in prepared culture medium and NRG-1 and lipopolysaccharide (LPS) were applied at the following final concentrations: LPS (10 μg/ml) and NRG-1 (100 ng/ml in 1 % BSA/PBS; recombinant human neuregulin1-beta1 EGF-like domain, R&D Systems). N9 cells were either pre-treated with NRG-1 (100 ng/ml) for 24 h followed by stimulation with LPS (10 μg/ml) or treated with LPS or NRG-1 alone for the indicated times (1–24 h).
Luminex multiplex enzyme-linked immunosorbent assay (ELISA)
Cell lysates were taken at 1, 3, 6, and 24 h time points following LPS treatment. The cytokine release was measured in cell culture supernatants by Luminex technology using the manufacturer’s protocol (Bio-Rad, Hercules, CA). Data analysis was performed using Bio-Plex Manager software on the Bio-Plex 200 system. Experiments were performed four times in duplicate wells.
Protein isolation and western blot
Proteins were isolated using whole cell extraction reagent M-PER (Pierce Biotechnology, Rockford, IL) or NE-PER Nuclear and Cytoplasmic Extraction Reagent (Thermo Scientific) according to the manufacturer’s instructions. Protein concentrations were determined by Bradford protein assay (Bio-Rad). Fifty micrograms of protein lysate was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes (PVDF) (Bio-Rad, CA). The membranes were blocked with 3 % nonfat dry milk in 0.1 % Tween-20/Tris-buffered saline for 1 h at room temperature and subsequently incubated with the primary antibodies overnight, followed by incubation in corresponding secondary horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Blots were developed using immuno-western star ECL detection kits (Bio-Rad). The optical densities of the antibody-specific bands were analyzed by a Luminescent Image Analyzer, LAS-4000 (Fuji, Japan). The following antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA) were used: NF-kB p65 (sc-372; 1:200), IkB-α (sc-371; 1:200), YY1 (sc-281; 1:200), and β-actin (sc-130656; 1:200).
IkB-α (total/phospho) InstantOne ELISA
The phosphorylation of IkB-α was determined using an enzyme-linked immunosorbent assay (ELISA)-based assay kit according to the manufacturer’s protocol (Affymetrix eBioscience, San Diego, CA). To analyze the results, we calculated the average values for each treatment group. This assay was run four times in duplicate.
Active motif transAM NF-kB family ELISA
Nuclear extracts were isolated using NE-PER Nuclear and Cytoplasmic Extraction kit according to the manufacturer’s protocol (Thermo Scientific, Waltham, MA). ELISA was performed using the manufacturer’s protocol. To analyze the results, the optical density was read using 450 nm with an optional reference wavelength of 655 nm. This assay was run three times in duplicate.
Statistical analysis for ELISAs and western blot data was performed by ANOVA with Tukey’s post hoc test for multiple comparisons where indicated. Significance was determined using a p value less than 0.05.
CONFAC analysis predicts transcription factor NF-kB to be regulated following MCAO + NRG1
Inflammatory genes induced by ischemia and downregulated by NRG-1
A kinase anchor protein 12
Actin-related protein 2/3 complex subunit 1B
Activating transcription factor 3
Benzodiazepine receptor (peripheral)-associated protein 1
CAMP responsive element modulator
Cartilage oligomeric matrix protein
CCAAT/enhancer-binding protein, delta
Cellular retinoic-binding protein 2
Crystallin, alpha B
Cytochrome P450 family 1
Deiodinase iodothyronine type III
Dyskeratosis congenita 1
Early growth response 1
Endothelin converting enzyme 1
Fx receptor, IgG, low-affinity III
Glycosylation-dependent cell adhesion molecule 1
Guanine nucleotide-binding protein gamma 11
Heat shock protein 4
High mobility group of box 2
Homer scaffolding protein 1
Inhibitor of DNA binding 1
Insulin-like growth factor-binding protein 3
Interleukin 1 beta
Isopentenyl-diphosphate delta isomerase 1
Kruppel-like factor 4
Lectin galatoside-binding soluble 2
Matrix gla protein
Matrix metallopeptidase 9
Mitogen-activated protein kinase e, E3
Oxidized low-density lipoprotein receptor 1
Phosphoribosyl pyrophosphate synthase-associated protein 1
Phosphorylase glycogen liver
Plasminogen activator tissue
Potassium channel member 12
Potassium channel, two pore domain subfamily K member 3
Protaglandin-endoperoxide synthase 2
Rentinol-binding protein 1
Ribosomal protein S15
S100 calcium-binding protein A10
S100 calcium-binding protein A4
S100 calcium-binding protein A8
S100 calcium-binding protein A9
Secreted phosphoprotein 1
Serpin peptidase inhibitor
Thyrotropin releasing hormone
TIMP metallopeptidase inhibitor 1
V-ETS avian erythroblastosis virus E26 oncogene homolog 1
VGF nerve growth factor inducible
NRG-1 suppressed the release of cytokines TNF-α and IL-6 in LPS-stimulated N9 microglial cells
NRG-1 attenuated LPS-stimulated phosphorylation and degradation of IkB-α in N9 microglial cells
NRG-1 attenuated P65 nuclear translocation in N9 microglia cells
NRG-1 increased the nuclear translocation of the P52 subunit
NRG-1 increased anti-apoptotic cytokines G-CSF and IL-9
NRG-1 has been shown to be neuroprotective and reduce inflammation in experimental models of ischemic stroke and neuroinflammation [1, 2, 3, 9, 10]; however, the molecular mechanism involved remains to be elucidated. Using CONFAC software, we were able to predict that the ability of NRG-1 to suppress ischemia-induced pro-inflammatory genes involved the modulation NF-kB pathways. NF-kB is known to be a master regulator of inflammation, which is the key contributor the pathology of ischemic stroke . In post-mortem human brain samples of stroke patients, the NF-kB p65 subunit in particular has been found around the necrotic infarct core . The NF-kB canonical pathway involves the phosphorylation and degradation of IkB leading to the nuclear translocation of p65/p50 NF-kB heterodimers to the nucleus where they stimulate the production of pro-inflammatory molecules [23, 24]. Using microglial cell cultures, we demonstrated that NRG-1 inhibited the LPS-induced phosphorylation and degradation of IkB-α, while also reducing the nuclear translocation of p65. This suggests that the mechanisms behind the anti-inflammatory/neuroprotective effects of NRG-1 involve the attenuation of the canonical NF-kB pathway.
The transcription factors identified by CONFAC did not change in mRNA expression in our analysis, including NF-kB family members. One of the primary reasons we chose a computational tool such as CONFAC is that it predicts transcription factors that change in activity, but not necessarily mRNA or protein levels. Indeed, induction of pro-inflammatory gene expression by NF-kB requires that cytoplasmic NF-kB p65/p50 translocates to the nucleus, but a change in NF-kB protein levels is not needed to mediate this effect. Over-representation of the NF-kB p65 TFBS indicates that it is more prevalent in the promoters of the genes in our dataset compared to a random set of genes. It does not indicate whether that promoter is activated or inhibited by the experimental paradigm. What our data suggest is that stroke causes transcriptional activation via the NF-kB p65-binding site, and NRG-1 prevents the binding of p65 to the TFBS by sequestering it in the cytoplasm.
The alternative NF-kB pathway is thought to have anti-inflammatory and anti-apoptotic roles [31, 35]. The alternative pathway activates NIK, a member of the MAP kinase family, which activates IKKα, resulting in the translocation of RelB/p52 NF-kB heterodimers to the nucleus. NIK-mediated activation of NF-kB is associated with the induction of anti-apoptotic and anti-inflammatory cytokines [30, 34, 37, 38, 50, 54, 55]. The alternative pathway is delayed relative to the canonical pathway, and only certain inducers are able to induce its activation . In microglial cells, NRG-1 administration increased the nuclear levels of p52. In addition to dimerization with RelB, the p52 subunit is also able to homodimerize and considered to have a repressive role due to its lack of a transcription activation domain . It has been previously shown that NRG-1 activates NIK . These finding indicate that NRG-1 could both activate the alternative pathway and/or suppress NF-kB transcriptional activity via p52 [23, 32, 56].
Previous studies demonstrated that NRG-1 can activate the NF-kB signaling pathway cancer cells and Schwann cells [40, 41, 42, 43, 44, 45, 46]. In these studies, it appears that NRG-1 signals by activating NF-kB p65; however, the activation of NF-kB by NRG-1 in breast cancer cells is associated with the increased expression of anti-apoptotic genes. The discrepancy in the findings may be due to the differential expression of erbB receptors on the cells. In cancer cells and Schwann cells, NRG-1 signals through erbB2 and erbB3 receptors. Neuroprotection in stroke by NRG-1 is mediated by erbB4 which physically associates with NIK [46, 57]. Interestingly, NRG-1 alone has little effect on NF-kB in our in vitro studies. So, the anti-inflammatory effects of NRG-1 appear to be contextually related to the presence on a pro-inflammatory response.
Consistent with regulation of the alternative NF-kB pathway, NRG-1 induced the production of G-CSF and IL-9 in cell cultures. G-CSF has been shown to be neuroprotective in ischemic stroke models by inducing anti-apoptotic pathways, and IL-9 is known to promote cell proliferation and inhibit apoptosis [53, 58]. It has been reported that G-CSF significantly reduced the expression of microglial p65, reduced pro-inflammatory mediators, and promoted anti-inflammatory responses in models of multiple sclerosis [59, 60]. There are reports which suggest that IL-9 may have the ability to downregulate specific sets of genes induced by NF-kB by inducing the expression of BCL-3 . BCL3 is an IkB protein that specifically associates with homodimers p50 and p52 and has been shown to regulate pro-survival genes. BCL3 is also able to repress transcription by increasing p52 homodimer binding to kB sites on DNA .
Stroke is a leading cause of death and disability in the USA. There is an urgent need to better understand the pathophysiology associated with stroke in order to develop more effective therapies. Here, we show that the neuroprotective and anti-inflammatory effects of NRG-1 are associated with the regulation of both canonical and alternative NF-kB signaling pathways. NRG-1 is currently in clinical trials for heart failure and has been shown to be safe and efficacious in phase I and phase II patient studies [63, 64]. These findings have major implications for the development of NRG-1 as a clinical therapy for stroke and other inflammation-mediated disorders.
We thank Timothy Distel for technical support.
This project was supported in part by NIH grants U54 NS060659 and U54 RR026137, G12RR003034, and S21MD000101.
Availability of data and materials
Raw data are available on personal demand.
BF and LS conceived the study, participated in its design and coordination, and helped to draft the manuscript. MS, GF, and GN participated in its design and coordination of the study and helped to draft the manuscript. YL conducted the MCAO surgeries. LS and GN designed and performed the in vitro studies. LS, GF, and BF conducted the data analysis. All authors read and approved the final manuscript.
Patents related to the work being reported is held by the author (BF) without direct corporate involvement at the time.
Consent for publication
Ethics approval and consent to participate
The study protocol was approved by the Institutional Animal Care and Use Committee at Morehouse School of Medicine according to international guidelines prior to the initiation of experimentation.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.